Sodium Pyruvate Nasal Spray Treatment of COVID-19 Infection
Two Week Sub-chronic Double-blinded Placebo Controlled Trial Designed to Determine if Sodium Pyruvate Nasal Spray Will Reduce the Symptoms, Duration and Replication of COVID-19 Infection
Sponsor: Cellular Sciences, inc.
Listed as NCT04824365, this PHASE2/PHASE3 trial focuses on COVID-19 and remains completed. Sponsored by Cellular Sciences, inc., it has been updated 6 times since 2021, reflecting limited change activity. This study is part of the global effort to build evidence for infectious disease interventions.
Status Flow
Change History
6 versions recorded-
Feb 2025 — Present [monthly]
Completed PHASE2/PHASE3
-
Sep 2024 — Feb 2025 [monthly]
Completed PHASE2/PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2/PHASE3
Phase: PHASE2_PHASE3 → PHASE2/PHASE3
-
Dec 2022 — Jul 2024 [monthly]
Completed PHASE2_PHASE3
-
Sep 2022 — Dec 2022 [monthly]
Completed PHASE2_PHASE3
Status: Recruiting → Completed
▶ Show 1 earlier version
-
May 2021 — Sep 2022 [monthly]
Recruiting PHASE2_PHASE3
First recorded
Apr 2021
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Cellular Sciences, inc.
- Dynamic DNA Laboratories
- Family First Medical Research Center
- Missouri State University
- Trinity Health System
For direct contact, visit the study record on ClinicalTrials.gov .